WILLIAM LAWRENCE DREW, M.D., Ph.D.

WILLIAM LAWRENCE DREW, M.D., Ph.D.

William Drew

UCSF Medical Center at Mount Zion Room B 201 1600 San Francisco, CA 94115

About the Expert

W. Lawrence Drew is Chief of Infectious Diseases at UCSF Medical Center at Mount Zion and is an active consultant in infectious diseases. He directed the clinical microbiology laboratory at Mount Zion and is currently a director of the clinical virology laboratory at UCSF. He is a professor of both Laboratory Medicine and Medicine at UCSF.

Areas of Expertise

  • Infectious Diseases

Expert's Profile

With his training and experience, Dr. Drew is able to provide expert review and testimony in infectious diseases and medical microbiology. He enjoys the intellectual challenge of medical-legal activity and participating in the process.

Verified Credentials:

- American Board of Internal Medicine
- American Board of Internal Medicine, Infectious Disease Subspecialty
- American Board of Medical Microbiology
- American College of Physicians, Fellow
- American Academy of Microbiology

Education:

Dr. Larry Drew graduated from Holy Cross, Worcester, Mass. with an A.B. and from Jefferson Medical College, Philadelphia, where he was elected to AOA, the medical honor society. He remained at Jefferson to earn a PhD in experimental pathology (virology). After a medical internship at Jefferson, he served his residency in internal medicine at UCSF. This was followed by a fellowship in medical microbiology at the University of Washington.

Personal Achievements

Education

  • 1954-58 Holy Cross College, Worcester, Mass. - B.A.
  • 1958-62 Jefferson Medical College, Philadelphia, PA - M.D.
  • 1963-66 Jefferson Medical College, Philadelphia, PA
  • Experimental Pathology (Virology) - Ph.D.

Licenses

  • BOARD CERTIFICATIONS:
  • American Board of Internal Medicine (ABIM) 1970
  • ABIM Infectious Disease Subspecialty 1980
  • American Board of Medical Microbiology 1983
  • California License Number G11943

Organizations

  • Western Association of Physicians
  • Fellow, Infectious Disease Society of America
  • American Society for Microbiology
  • American Academy of Microbiology
  • Alpha Omega Alpha
  • Bay Area Infectious Disease Society, Vice President, 1971-1984, President, 1994 to present
  • American College of Physicians, 1990 to present
  • Pan American Society for Clinical Virology, Councillor 1996 to 2000
  • International AIDS Society, core faculty 1995-present

Honors

  • Scholarship - Regis High School
  • New York State College Scholarship, 1954
  • Francis Shain Scholarship - Jefferson Medical College, 1961
  • Alpha Omega Alpha - Jefferson Chapter, 1962
  • Hobart Hare Medical Honor Society - Jefferson Medical College, 1962
  • S.S. Cohen Prize in Medicine - 1962
  • Charles Labelle Prize as the Outstanding Graduate Student - 1966
  • Outstanding Teacher Award - Mount Zion Hospital and Medical Center 1971, 1974
  • Irving Slotnick Award Lecture - Cedars Sinai Memorial Hospital, Los Angeles,
  • California, November 1983.
  • Alberta Heritage Days, University of Alberta. Is CMV a Cofactor in AIDS? Invited
  • Keynote Speaker, Alberta Canada, November 22, 1985.
  • Edith Hsiung Lecture. Pan American Group for Rapid Viral Diagnosis. Clearwater,
  • Florida, 1992 and 1995.
  • Fellow, American College of Physicians, 1990 to present
  • Keynote Speaker IV International Symposium on Ocular Inflammation.
  • London England, September 1996.
  • Ortho-McNeill Annual Visiting Professor, Oregon Health Sciences University,
  • July 1997
  • UCSF Mount Zion Alumni and Staff Association Award of Distinguished
  • Alumnus for 1997
  • Fellow, American Academy of Microbiology, December 1997
  • Elected to American Board of Internal Medicine Subspecialty Board on Infectious Disease,
  • February 1998
  • Pan American Society for Clinical Virology, Clearwater, FL, April 2000
  • 3
  • Roche Diagnostics Corporation Lectureship
  • Jefferson Medical College, Jefferson Alumni Achievement Award, June 2000*
  • Elected to Best Doctors in America (SF Bay Area) from 1996-2003
  • Keynote Speaker, Cytomegalovirus Update. Western Association of Physicians 2008Western
  • Regional Meeting, Carmel, CA, February, 2008
  • *One award of significance is the Jefferson Medical College Alumni Achievement Award. This
  • yearly award is given to only one or two of all the alumni. Other recipients include Robert Gallo.
  • RESEARCH AWARDS AND GRANTS:
  • Current or Pending Research Grant and Contract Support:
  • 1. TRIPS (Transfusion-Related Infections Prospectively Studied), Subinvestigator. To evaluate
  • CMV transmission by blood transfusion, using PCR. (2002-2007/2011)
  • Sponsor: NIH/Blood Centers of the Pacific

Publications

  • PUBLICATIONS
  • Refereed
  • 1. Gilgore SG, Drew WL, Rupp JJ. The effects of salicylate on plasma non-esterified fatty
  • acids. Am J Med Sci 1963;245:456-68.
  • 2. Drew WL, Love R. Production of Herpes simplex virus by HeLa cells treated with 5-
  • Staphylococcus aureus infection. Observation in hospital and nursing home. JAMA
  • 1970;213(2):257-63.
  • 4. Drew WL, Pedersen AN, Roy JJ. An automated slide staining machine. Appl Micro
  • 1972;23:17-20.
  • Diffusion Method for detecting "Methicillin-Resistant" strains of Staphylococcus aureus. Appl
  • Micro 1972;24:240-47.
  • 6. Drew WL, Blume MR, Miner RC, Silverberg I, Rosenbaum EH. Herpes zoster: transfer
  • factor therapy. Ann Intern Med 1973;79:747-48.
  • 7. Hoo R, Drew WL. The potential unreliability of nitrofurantoin discs in susceptibility
  • testing. Antimicrob Ag & Chemoth 1974;5(6):607-10.
  • 8. Enlander D, Drew WL, Hoo R, Everhart TE, Scott T. The cytopathic effect of herpes
  • simplex virus on HE--2 cells as shown by scanning electron microscopy. J Gen Virol
  • 1974;25:313-16.
  • 9. Drew WL, Finley TN, Mintz L, Klein HZ. Diagnosis of Pneumocystis carinii pneumonia
  • by bronchopulmonary lavage. JAMA 1974;230(4):723-25.
  • 10. Ablow RC, Drew WL, Seys Y. Renal enlargement associated with infectious
  • mononucleosis. Pediat Radiol 1975;2:114-16.
  • 11. Golde DW, Drew WL, Klein HZ, Finley TN, Cline MJ. Occult pulmonary hemorrhage in
  • leukaemia. Brit Med J 1975;2:166-68.
  • 12. Enlander D, Remedios Dos LV, Weber PM, Drew WL. Radio-Immunoassay for Herpes
  • simplex virus. J Immuno Meth 1976;10(4):357-62.
  • 13. Drew WL, Finley TN, Golde DW. Diagnostic lavage and occult pulmonary hemorrhage in
  • thrombocytopenic immunocompromised patients. Am Rev Resp Dis 1977;116:215-21.
  • 18
  • 14. Drew WL. The value of sputum culture in the diagnosis of pneumococcal pneumonia. J
  • Clin Micro 1977;6:62-65.
  • 15. Palmer PES, Finley TN, Drew WL, Golde WD. Radiographic aspects of occult pulmonary
  • hemorrhage. Clin Radiol 1978:29:139-143.
  • 16. Montgomery K, Raymundo L, Drew WL. Chromogenic cephalosporin spot test to detect
  • Beta-lactamase in clinically significant bacteria. J Clin Micro 1979;9:205-207.
  • 17. Drew WL, Mintz L, Hoo R, Finley TN. Growth of herpes simplex virus and
  • cytomegalovirus in cultured human alveolar macrophages. Am Rev Resp Dis 1979;119:187-92.
  • 18. Ballard RA, Drew WL, Hufnagle KG, Riedel PA. Acquired cytomegalovirus infection in
  • preterm infants. Am J Dis Child 1979;133:482-85.
  • 19. Mintz L, Ballard RA, Sniderman SH, Roth RS, Drew WL. Nosocomial respiratory
  • syncytial virus infections in an intensive care nursery. Rapid diagnosis by direct
  • immunofluorescence. Pediatrics 1979;64:149-53.
  • 20. Drew WL, Mintz L. Rapid diagnosis of Varicella-Zoster virus infections by direct
  • immunofluorescence. Am J Clin Path 1979;73:699-701.
  • 21. Johnson MA, Drew WL, Roberts M. Branhamella (Neisseria) catarrhalis -a lower
  • respiratory tract pathogen? J Clin Micro 1981;13(6):1066-69.
  • 22. Mintz L, Drew WL, Hoo R, Finley TH. Age dependent resistance of human alveolar
  • macrophages to herpes simplex virus. Infec and Immun 1980;28:417-20.
  • 23. Drew WL, Mintz L, Miner RC, Sands M, Ketterer B. Prevalence of cytomegalovirus
  • infection in homosexual men. J Infect Dis 1981;143:188-192.
  • 24. Mintz L, Drew WL. Comparative synergistic activity of Cefoperazone, Cefotaxime,
  • Moxalactam, and Carbenicillin, combined with Tobramycin, against Pseudomonas aeruginosa.
  • Antimicrob Agents Chemother 1981;19:332-34.
  • 25. Drew WL, Miner R. Transfusion-related cytomegalovirus infection following noncardiac
  • surgery. JAMA 1983;247(17):2389-91.
  • 26. Bolan RK, Sands M, Shachter J, Miner RC, Drew WL. Lymphogranuloma Venereum and
  • Acute Ulcerative Proctitis. Am J Med 72:703-706, 1982.
  • 27. Lichtenstein H, Schwartzbord SF, Drew WL, Feigenbaum LZ, Brownstein H. Delayed
  • hypersensitivity skin reactions in the elderly. J Am Ger Soc July 1982;30:447-48.
  • 19
  • 28. Drew WL, Miner RC, Ziegler JL, Gullett JH, Abrams DI, Conant MA, Huang ES,
  • homosexual men. Lancet 1982;2:125-27.
  • 29. Follansbee SE, Busch DF, Wofsy CB, Coleman DL, Gullett J, Aurigemma GP, Ross T,
  • Hadley WK, Drew WL. An outbreak of Pheumocystis carinii pneumonia in homosexual men.
  • Ann In Med 1982;96(Part One):705-13.
  • 30. Ziegler JL, Drew WL, Miner RC, Mintz L, Rosenbaum E, Gershow J, Lennette ET,
  • lymphoma in homosexual men. Lancet 1982;2:631-33.
  • 31. Mintz L, Drew Wl, Miner RC, Braff EH. Cytomegalovirus Infections in Homosexual Men:
  • An Epidemiological Study. Ann Intern Med 1983;99(3)326-329.
  • 32. Black SB, Raas M, Mintz L, Shinefield HR, Drew WL. Indirect hemagglutination
  • inhibition: A direct method for detecting cytomegalovirus antigen. J Clin Lab Med 1983;101:450-
  • 452.
  • 33. Weintraub PS, Koerper MA, Addiego JE, Drew WL, Lennette ET, Miner RC, Cowan MJ,
  • Ammann AJ. Immunological abnormalities in patients with hemophilia A. J Pediatr 103: (5)951-
  • 955, 1983.
  • 34. Abrams DI, Lewis BJ, Beckstead JH, Cassavant CA, Drew WL. Persistent diffuse
  • lymphadenopathy in homosexual men: Endpoint or prodrome? Ann Intern Med 100:801-808,
  • 1984.
  • 35. Katznelson S, Drew WL, Mintz L: Efficacy of the condom as a barrier to the transmission
  • of cytomegalovirus. J Infect Dis 150: 155-157, 1984.
  • 36. Drew WL, Mocarski ES, Sweet E, Miner RC: Multiple infections by cytomegalovirus in
  • patients with AIDS: Documentation by southern blot hybridization. J Infect Dis 150:952, 1984.
  • 37. Drew WL, Mills J, Levy, JA, Dylewski J, Cassavant C, Ammann A, Brodie H, Merigan
  • TC: Cytomegalovirus infection and abnormal T lymphocyte subsets in homosexual men. Ann Int
  • Med 103:61-63, 1985.
  • 38. Plotkin SA, Drew WL, Felenstein D, and Hirsch MS: Sensitivity of clinical isolates of
  • human cytomegalovirus to 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine. J Infect Dis 152:833-
  • 834, 1985.
  • 39. Collaborative DHPG Treatment Study Group:
  • Treatment of serious CMV infection using DHPG in patients with AIDS and other
  • immunodeficiencies. N Eng J Med 314:801-805, 1986.
  • 20
  • 40. Gerberding JL, Bryant-LeBlanc CE, Nelson K, Moss AR, Osmond D, Chambers HE,
  • Carlson JR, Drew WL, Levy JA, Sande MA: Risk of transmitting the human immunodeficiency
  • virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS
  • and AIDS-related conditions. J Infect Dis 156:1-8, 1987.
  • 41. Gold D, Ashley R, Handsfield HH, Verdon M, Leach L, Mills J, Drew L, Corey L:
  • Immunoblot analysis of the humoral immune response in primary cytomegalovirus infection. J
  • Infect Dis 157:319-326, 1988.
  • 42. Drew WL, Mills J, Hauer LB, Miner RC, Rutherford GW: Declining prevalence of
  • Lancet 1: 66, 1988.
  • 43. Drew WL: Cytomegalovirus infection in patients with AIDS. AIDS Commentary. J Inf
  • Dis 158:449-456, 1988.
  • 44. Drew WL, Ehrlich KS: Herpesviruses in AIDS patients, Part 2: Herpes simplex and
  • varicella zoster. J Critical Illness 4:92-102, 1989.
  • 45. Jespersen DJ, Drew WL, Gleaves CA,: Multisite evaluation of a monoclonal antibody
  • reagent (Syva) for rapid diagnosis of cytomegalovirus in the shell vial assay. J Clin Microbiol
  • 27:1502-5, 1989.
  • 46. Baxter RP, Chapman J, and Drew WL: Comparison of bactericidal activity of five
  • antibiotics against Staph aureus. J Infect Dis 161:1023-1025, 1990.
  • 47. Dworkin RJ and Drew WL: Survival of cytomegalovirus in blood bank blood. J Infect Dis
  • 161:1310-1311, 1990.
  • 48. Drew WL, Blair M, Miner RC and Conant M: Evaluation of a new female condom for
  • virus permeability. Sex Transm Dis. 17(2):110-112, 1990.
  • 49. Rabella N and Drew WL: Comparison of conventional shell vial cultures for detecting
  • cytomegalovirus infection. J Clin Microbiol 28:806-807, 1990.
  • 50. Drew WL, Miner RC, Busch DF et al: Prevalence of resistance in patients receiving
  • ganciclovir for serious CMV infection. J Infect Dis 163:716-719, 1991.
  • 51. Drew WL, Miner RC, King D: Antiviral activity of FIAU versus strains of CMV sensitive
  • and resistant to ganciclovir. J Infect Dis 163:1388-1389, 1991.
  • 52. Jacobson MA, Drew WL, Feinberg J,: Foscarnet therapy for ganciclovir-resistant
  • cytomegalovirus retinitis in patients with AIDS. J Infect Dis 163:1348-1351, 1991.
  • 53. Drew WL: Clinical use of ganciclovir for cytomegalovirus infection and the development
  • of drug resistance. J Acq Imm Def Synd 4(Supp 1):S42-S46, 1991.
  • 21
  • 54. Shimozuma M, Drew WL, Miner RC, Epstein WL, Fukuyama K: Direct inactivation of
  • herpes simplex viruses by rat epidermal protein. Antiviral Research 18:179-189, 1992.
  • 55. Stanat SC, Reardon J, Erice A, Jordan C, Drew WL, Biron KK: Ganciclovir-resistant
  • HCMV clinical isolates: mode of resistance to ganciclovir and antiviral drug susceptibility profiles.
  • Antimicrob. Agents Chemother 35:2191-2197, 1991.
  • 56. Drew WL: Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 14:608-15,
  • 1992.
  • 57. Drew WL: Nonpulmonary manifestations of cytomegalovirus infection in
  • immunocompromised patients. Clin Micro Rev. 5:204-210, 1992.
  • 58. Drew WL, Miner R, Saleh E: Antiviral Susceptibility Testing of Cytomegalovirus: Criteria
  • for Detecting Resistance to Antivirals. Clinical and Diagnostic Virology 1:179-185,1993
  • 59. Lalezari JP, Drew WL, Glutzer E,: Treatment with intravenous (S)-1[3-Hydroxy-2-
  • (phosphonylmethoxypropyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes
  • simplex virus in a patient with AIDS. J Infect Dis 170:570-572,1994.
  • 60. Lifson AR, Olsen R, Robert S, Poscher ME, Drew WL, Conant MA: Severe opportunistic
  • infections in AIDS patients with late-stage disease. J Am Bd Fam Prac, July-August 1994.
  • 61. Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J: Failure of highdose oral
  • acyclovir to suppress CMV excretions in HIV antibody positive patients. J AIDS 8:289-291,1995.
  • 62. Lalezari JP, Drew WL, Glutzer E, James C, Miner RC, Flaherty J, Fisher PE, Cundy K,
  • Hannigan J, Martin JC, Jaffe HS: (S)-1-[3-Hydroxymethoxy)propyl]cytosine (Cidofovir):Results
  • of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 171:788-796,1995.
  • 63. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA,
  • Friedberg D, Hubbard L, Stempien MJ, Shadman A, Buhles W for the Syntex Cooperative Oral
  • Ganciclovir Study Group: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis
  • in patients with AIDS. New Engl J Med 333:615-620,1995
  • 64. Spector SA, Busch DF, Follansbee D, Squires K, Lalezari JP, Jacobson JD, Connor JD,
  • Jung D, Shadman A, Mastre B, Buhles W, Drew WL: Pharmacokinetic, safety, and antiviral
  • profiles of oral ganciclovir in persons infected with human immonodeficiency virus: a phase I-II
  • study. J Infect Dis 171:1431-7;1995.
  • 65. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97
  • phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates.
  • J Infect Dis 172:239-242;1995.
  • 22
  • 66. Cherrington JM, Miner RC, Hitchcock MJM, Lalezari JL, Drew WL. Susceptibility of
  • human cytomegalovirus (HCMV) to cidofovir is unchanged after limited in vivo exposure to
  • various clinical regimens of drug. J Infect Dis 173:987-992,1996
  • 67. van der Meer JTM, Drew WL, Bowden RA, Galasso GJ, Griffiths PD, Jabs DA, Katlama
  • C, Spector SA, Whitley RJ. Summary of the International Consensus Symposium on Advances in
  • the Diagnosis, Treatment and Prophylaxis of Cytomegalovirus Infection. Antiviral Research
  • 1996;32:119-40.
  • 68. Jacobson MA, Drew WL, Dunn JP et al, for the Studies of Ocular Complications of AIDS
  • (SOCA) in collaboration with the AIDS Clinical Trial Group: Cytomegalovirus (CMV) culture
  • results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with
  • either foscarnet or ganciclovir. J Infect Dis 176:50-8,1997.
  • 69. Flood J, Drew WL, Miner RC, Jekic-McMullen D, Shen L-P, Kolberg J, Garvey J,
  • Follansbee S, Poscher M. Diagnosis of cytomegalovirus (CMV) polyradiculopathy and
  • documentation of in-vivo anti-CMV activity in cerebrospinal fluid using branched DNA signal
  • amplification and antigen assays. J Infect Dis 176:50-8,1997.
  • 70. Rasmussen L, Hong C, Zipeto D, Morris S, Sherman D, Wolitz R, Dowling A, Warford A,
  • Miner RC, Drew WL, Chou S, and Merigan TC. Cytomegalovirus gB genotype distribution
  • differs in human immunodeficiency virus-infected patients and immunocompromised allograft
  • recipients. J Infect Dis 175:179-184,1997.
  • 71. Lalezari JP, Stagg RJ, Kupperman BD, Holland GN, Kramer F, Ives DV, Youle M,
  • Robinson MR, Drew WL, Jaffe HS. Intravenous cidofovir for peripheral cytomegalovirus retinitis
  • in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126:257-263,1997.
  • 72. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS,
  • Mulato AS, Lamy PD, Weixing L, Cherrington JM, Hellmann N, Kahn J. The safety and efficacy
  • of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV infected
  • adults. A randomized, double-blind, placebo controlled trial. J Infect Dis 176:1517-1523,1997.
  • 73. Chernoff DN, Miner RC, Hoo BS, Shen L-P, Kelso RJ, Jekic-McMullen D, Lalezari JP,
  • Chou S, Drew WL, Kolberg JA: Quantification of CMV DNA in peripheral blood leukocytes
  • using a branched DNA (bDNA) signal amplification assay. J Clin Micro 35:2740-2744,1997.
  • 74. Lalezari J, Schackler T, Feinberg J, Gathe J, Lee S, Cheung T, Kramer F, Kessler H, Drew
  • WL, Boggs J, McGuire B, Jaffe HS, and Safrin S. A randomized, double-blind, placebo-controlled
  • trial of cidofovir topical gel for the treament of acyclovir-unresponsive mucocutaneous herpes
  • simplex infection in patients with AIDS. J Infect Dis 176:892-898,1997.
  • 75. Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, Miner RC,
  • Drew WL. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy
  • for cytomegalovirus disease. J Infect Dis 176:786-789, 1997.
  • 23
  • 76. USPHS/IDSA Working Group. 1997 USPHS/IDSA guidelines for the prevention of
  • opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med
  • 127:922-946,1997.
  • 77. Sande M, Armstrong D, Corey L Drew WL, Gilbert D, Moellering RC, Smith LG.
  • Perspectives on a switch of oral acyclovir from prescription to OTC status: report of a consensus
  • panel. Clin Infect Dis 26:659-663, 1998.
  • 78. Chou S, Marousek G, Parenti DM, Gordon SM, LaVoy AG, Ross JG, Miner RC, Drew
  • WL. Mutation in region III of the DNA polymerase gene associated with foscarnet resistance in
  • cytomegalovirus (CMV) isolates from three subjects receiving prolonged antiviral therapy. J Infect
  • Dis 178:526-530,1998.
  • 79. Long CM, Drew WL, Miner RC. Detection of cytomegalovirus in plasma and
  • cerebrospinal fluid specimens from human immunodeficiency virus-infected patients by the
  • AMPLICOR CMV test. J Clin Micro 36:2434-2438,1998.
  • 80. Whitley R, Jacobson M, Benson C, Deutsch T, Dieterich D, Drew WL. Guidelines for the
  • treatment of cytomegalovirus disease in patients with AIDS in the era of potent antiretroviral
  • therapy. Recommendations of an international panel. Arch of Intern Med 158:957-969,1998.
  • 81. Cherrington JM, Fuller MD, Lamy PD, Miner RC, Lalezari JP, Nuessle S, Drew WL. In
  • vitro antiviral susceptibilities of isolates from CMV retinitis patients receiving first- or second-line
  • cidofovir therapy: relationship to clinical outcome. JID 178:1821-1825,1998.
  • 82. Mazzulli T, Drew WL, Yen-Lieberman B, Jekic-McMullen D, Kohn D, Isada C, Moussa
  • G, Chua R, Walmsley S. Multicenter comparison of the Digene Hybrid Capture CMV DNA
  • Assay (version 2.0) pp 65 antigenemia assay and cell culture for detection of cytomegalovirus
  • viremia. J Clin Micro 37:958-963,1999.
  • 83. Drew WL, Stempien MJ, Andrews J, Shadman A, Tan S-J, Miner RC, Buhles W.
  • Cytomegalovirus resistance in patients with CMV retinitis and AIDS treated with oral or
  • intravenous ganciclovir. J Infect Dis 179:1352-1355, 1999.
  • 84. Martin DF, Kupperman BD, Wolitz RA, Palestine AG, Li H, Robinson CA, and the Roche
  • Ganciclovir Study Group. Oral ganciclovir in patients with cytomegalovirus retinitis treated with a
  • ganciclovir implant: a randomized controlled clinical trial. NEJM 340:1063-70,1999
  • 85. O’Sullivan C, Drew WL, McMullen D, Miner RC, Lee JY, Kaslow RA, Lazar J, Saag M.
  • Decrease of cytomegalovirus replication in human immunodeficiency virus infected patients after
  • treatment with highly active antiretrovirual therapy. J Infect Dis 180:847-849,1999.
  • 86. USPHS/IDSA Working Group. 1999 USPHS/IDSA guidelines for the prevention of
  • opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med
  • 131:873-908,1999.
  • 24
  • 87. Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, A
  • standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus
  • clinical isolates. Antimicrob Agents and Chemo 2000;44:688-692.
  • 88. Drew WL. Invited Commentary. Ganciclovir resistance: A matter of time and titre. Lancet
  • 2000;356:609-610.
  • 89. Kalish LA, et al, for the Viral Activation Transfusion Study Group. Plasma human
  • immunodeficiency virus (HIV) type 1 RNA load in men and women with advanced HIV-1 disease.
  • J Infect Dis 2000;182:603-606.
  • 90. Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus
  • DNA polymerase sequence confers multidrug resistance. J Infect Dis 2000;182:1765-1768.
  • 91. Collier AC, Kalish LA, Busch MP, Holland P, for the Viral Activation Transfusion Study
  • Group. Leukocyte-reduced red blood cell transfusions in patients with anemia and human
  • immunodeficiency virus infection. JAMA 285:1592-1601,2001.
  • 92. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M-L, Davis C, Boeckh M.
  • Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogenic
  • hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
  • Blood 97:867-74,2001
  • 93. Roback JD, Hillyer CD, Drew WL, Laycock ME, Luka J, Mocarski ES, Slobedman B,
  • Smith JW, Soderberg-Naucler C, Todd DS, Woxenius S, Busch MP. Multicenter evaluation of
  • PCR methodologies to detect cytomegalovirus (CMV) DNA in blood donors. Transfusion
  • 2001;41:1249-57.
  • 94. Para MF, Kalish LA, Collier AC, Pollard RB, Kumar PN, Mintz L, Wallach FR, Drew WL.
  • Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV
  • infection who require transfusions. J Acquir Immune Defic Syndr 2001;26:320-5.
  • 95. Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL. Correlates of change in
  • cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who
  • require transfusion. J Infect Dis 2001;183:1673-7.
  • 96. Drew WL, Paya CV, Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J
  • Transplantation 2001;1:307-12. (Invited)
  • 97. Mousavi-Jazi M, Schloss, Drew WL, Linde A, Miner RC, Harmenberg J, Wahren B,
  • Brytting M. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in
  • relation to foscarnet and ganciclovir sensitivity. J Clin Virol 2001;23:1-15.
  • 98. Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, Drew WL.
  • Cytomegalvirus UL 97 phosphotransferase mutations that affect susceptibility to ganciclovir. J
  • Infect Dis 2002;185:162-9.
  • 25
  • 99. Lalezari JP, Friedberg DN, Bissett J, Giordano MF, Hardy WD, Drew WL. High dose oral
  • ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol 2002;24:67-77.
  • 100. Drew WL, Chou S, Miner RC, Mohr BA, Busch MP, Van der Horst CM, Asmuth DM,
  • Kalish LA. Cytomegalovirus glycoprotein B groups in HIV-infected patients with incident
  • retinitis. J Infect Dis 2002;186:114-7.
  • 101. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S,
  • Jacobson MA, Drew WL. A phase I dose-escalation trial evaluating the pharmacokinetics, antihuman
  • cytomegalovirus (HCMV), activity, and safety of 1263W94 in human immunodeficiency
  • virus-infected men with asymptomatic HCMV shedding. Antimicrobial Agents Chemother
  • 2002;46:2969-76.
  • 102. Drew WL, Tegtmeier G, Alter HA, Laycock ME, Miner RC, Busch MP. Frequency and
  • duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion
  • 2003;43:309-313.
  • 103. Roback JD, Drew WL, Laycock ME, Todd D, Hillyer CD, Busch MP. Cytomegalovirus
  • DNA is Rarely Detected in Healthy Blood Donors Using Validated PCR Assays.
  • Transfusion 2003;43:314-21.
  • 104. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase
  • mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003;188:32-9.
  • 105. Drew WL, Chou S, Mohr BA, Assmann SF, Miner RC, Laycock ME, Busch MP for the
  • Viral Activation Transfusion Study (VATS) Group. Absence of activation of CMV by blood
  • transfusion to HIV-infected, CMV-seropositive patients. Transfusion 2003;43:1351-1357.
  • 106. Imai Y, Shum C, Martin DF, Kupperman BD, Drew WL, Margolis TP. Emergence of
  • drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with
  • ganciclovir. J Infect Dis 2004;189:611-5.
  • 107. Flanders SA, Stein J, Shochat G, Sellers K, Holland M, Maselli J, Drew WL, Reingold AL,
  • Gonzales R. Performance of a bedside C-reactive protein test in the diagnosis of communityacquired
  • pneumonia in adults with acute cough. Am J Med 2004;116:529-35.
  • 108. Louie JK, Hacker JK, Gonzales R, Mark J, Maselli JH, Yagi S, Drew WL.
  • Characterization of viral agents causing acute respiratory infection in a San Francisco university
  • medical center clinic during the influenza season. Clin Infect Dis 2005;41:822-8.
  • 109. Stein J, Louie J, Flanders S, Maselli J, Hacker JK, Drew WL, Gonzales R. Performance
  • characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the
  • detection of influenza infection in a community sample of adults. Annals of Emergency Medicine
  • 2005;46:412-9.
  • 26
  • 110. Roback JD, Conlan M., Drew WL, Ljungman P, Nichols WG, and
  • Preiksaitis JK. The role of photochemical treatment with amotosalen and UVA light in the
  • prevention of transfusion-associated cytomegalovirus infections. Transf Med Rev 2006;20:45-56.
  • 111. Drew WL. Is combination antiviral therapy for CMV superior to monotherapy? J Clin
  • Virol 2006;35:485-8.
  • 112. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus
  • isolates resistant to ganciclovir, cidofovir, or foscarnet. J Clin Virol 2006;37:124-7.
  • 113. Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL. Development of new
  • cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after
  • valganciclovir therapy in allogenic stem cell recipients. J Clin Virol 2007;38:120-5.
  • 114. Drew WL, Roback JD. Prevention of transfusion-transmitted cytomegalovirus:
  • reactivation of the debate? Transfusion 2007;47:1955-8.
  • 115. Heiden D, Ford N, Wilson D, Rodriguez WR, Margolis T, Janssens B, Bedelu M, Tun N,
  • Goemaere E, Saranchuk P, Sabapathy K, Smithuis F, Luyirika E, Drew WL. (2007)
  • Cytomegalovirus retinitis: the neglected disease of the aids pandemic. PLoS Med 4(12): e334.
  • doi:10.1371/journal.pmed.0040334.
  • 116. Chiu CY, Urisman A, Greenhow TL, Rouskin S, Yagi S, Schnurr D, Wright C, Drew WL,
  • et al. Utility of DNA microarrays for detection of viruses in acute respiratory tract infections in
  • children. J Pediatrics 2008;153:76-83.
  • 117. Burbelo PD, Issa AT, Ching KH, Exner M, Drew WL, Alter HJ, Iadarola MJ. Highly
  • quantitative serological detection of anti-cytomegalovirus (CMV) antibodies. Virology Journal
  • 2009;6:45.
  • 118. Drew WL. Cytomegalovirus resistance testing: Pitfalls and problems for the clinician.
  • Clin Infec Dis 2010;50:733-6.
  • 119. Liu C, Schwartz BS, Vallabhaneni S, Nixon M, Chin-Hong PV, Miller SA, Chiu C,
  • Damon L, Drew WL. Pandemic (H1N1) 2009 infection in patients with hematologic malignancy.
  • Emerg Infect Dis 2010;16:1910-17.
  • 27
  • BOOKS AND MONOGRAPHS EDITED
  • Drew WL (ed): Viral Infections - a clinical approach, Philadelphia F.A. Davis Co., 1976.
  • Drew WL, Grossman M. Clinical Virology. MedCom Famous Teachings in Modern
  • Medicine, MedCom, Inc., New York, N.Y., 1973 (Slides and Text). Revised 1983.
  • Drew WL. Coordinating editor. Laboratory Diagnosis of Viral Infections. ASM,
  • Washington, D.C., 1982.
  • Drew WL. Coordinating editor. Laboratory Diagnosis of Chlamydia and Mycoplasmal
  • Infections. ASM, Washington, D.C., 1984.
  • Drew WL. Genital Herpes Simplex Infection: Current Understanding, Diagnosis and
  • Treatment. MedCom Famous Teachings in Modern Medicine, MedCom, Inc., Garden
  • Grove, California, 1985. (Slides and Text).
  • Drew WL. Coordinating editor. Diagnosis and Treatment of Viral Infections. W.B.
  • Saunders, Philadelphia. Clinics in Laboratory Medicine, vol 7, no. 4, 1987.
  • Drew WL. Editor. Laboratory Diagnosis of Viral Disease.ASM,Washington D.C., 1985.
  • Drew WL (ed): Virology section. In Murray, PR, Drew WL, Kobayashi G, and Thompson J (eds):
  • Medical Microbiology, Chapters 38-57, pp. 439-685, the C. V. Mosby Co., St. Louis, 1990.
  • Drew WL. (associate ed): Medical Microbiology: An Introduction to Infectious Diseases. Edited
  • by Ryan K. Appleton and Lange, Norwalk, CT, 1994.
  • Drew WL. Associate Editor: Current Diagnosis and Treatment in Infectious Diseases. Lange
  • Medical Books/McGraw-Hill, New York, 2001.
  • Drew WL. Guest Editor: Clinics in Laboratory Medicine. Emerging and Re-Emerging
  • Infections. Volume 22, Number 4, Elsevier Science USA, 2002.
  • Drew WL. (associate ed): Sherris Medical Microbiology: An Introduction to Infectious Diseases.
  • Edited by Ryan K and Ray C. George. McGraw Hill, Medical Publishing Division, New York,
  • NY, 2003.
  • Drew WL. (associate ed): Sherris Medical Microbiology: An Introduction to Infectious Diseases.
  • Edited by Ryan K and Ray C. George. McGraw Hill, Medical Publishing Division, New York,
  • NY, 2009.
  • 28
  • CHAPTERS WRITTEN
  • 1. Drew WL. Epidemiology of Cytomegalovirus, in de la Maza LM, Peterson EM (eds):
  • Medical Virology. New York, Elsevier Science Publishing Co., Inc. 1982;183-195.
  • 2. Drew WL, Mintz L. Cytomegalovirus infection in healthy and immune deficient
  • homosexual men, in Ma P, Armstrong D (eds): The Acquired Immune Deficiency
  • Syndrome and Infections of Homosexual Men. New York, Yorke Medical Books. 1983:
  • 117-123.
  • 3. Mintz L, Drew WL. Sexually transmitted viral infection in homosexual men. In de la
  • Maza L (ed): Med Clin North Am; Medical Virology 1983;67:5:1093-1105.
  • homosexual men, in Plotkin S, Michelson S, Pagano JS and Rapp F, (eds): CMV:
  • Pathogenesis and Prevention of Human Infection. New York, Alan R. Liss, Inc., 1984:
  • 121-129.
  • 5. Drew WL and Rawls WE. Herpes simplex viruses, in Lennette EH, Balows A,
  • Hausler WJ Jr., and Shadomy HJ (eds): Manual of Clinical Microbiology. Washington
  • D.C., American Society for Microbiology, 1985.
  • 6. Drew WL. Laboratory diagnosis of viral skin disease, in Rook AJ and Maibach HI
  • (eds): Seminars in Dermatology. New York, Thieme-Stratton, Inc., 1984: 24-32.
  • 7. Drew WL. Diagnosis and treatment of cytomegalovirus (CMV) infections in Mills
  • and Corey (eds): Antiviral Chemotherapy. New Directions for Clinical Application and
  • Research. Elsevier, New York, 1986: 280-289.
  • 8. Drew WL. Laboratory methods in basic virology, in Finegold and Baron (eds):
  • 677.
  • 9. Drew WL, Huang ES: Etiology: Role of cytomegalovirus, in Ziegler JL and
  • York, Marcel Dekker, Inc., 1987, 113-128.
  • 10. Drew WL, Buhles W, Ehrlich, KS: Herpesvirus infections (cytomegalovirus,
  • herpes simplex virus, varicella-zoster virus). How to use ganciclovir (DHPG) and
  • acyclovir in Moellering RC Jr. MD (ed): Medical Management of AIDS. Infectious
  • Disease Clinics of North America 2(2): 495-509, 1988.
  • 29
  • 11. Drew WL: Cytomegalovirus, in Balows A, et al (eds): Laboratory Diagnosis in
  • Infectious Disease. Principles and Practice. vol I, Springer-Verlag, New York, 1988, p.
  • 247-260.
  • 12. Drew WL: Other virus infections in AIDS. Cytomegalovirus, in Levy J (ed):
  • AIDS. Pathogenesis and Treatment. Marcel Dekker, Inc., New York, 1988, p. 507- 34.
  • 13. Drew WL and Matthews TR: Susceptibility testing of herpes viruses. Clinics in
  • Laboratory Medicine Vol 9., No. 2, June 1989, p. 279-286.
  • 14. Drew WL: CMV as a sexually transmitted disease, in Huang and Alford (eds):
  • Disease Caused by Human Cytomegalovirus. Boston, Klumer Academic Publishers, 1989.
  • 15. Drew WL: Clinical Indications for virologic diagnosis in Remington J and Swartz
  • M (eds): Current Clinical Topics in Infectious Disease. vol 10, Blackwell Scientific
  • Publishers, Boston, pp. 158-172, 1989.
  • 16. Drew WL and Mintz L: Cytomegalovirus in healthy and immune deficient
  • homosexual men, in, Ma and Armstrong (eds): AIDS and Infections of Homosexual Men,
  • Second Edition. Butterworths, Boston, 1989, pp. 119-130.
  • 17. Drew WL, Buhles W, Dworkin RJ and Ehrlich KS: Management of virus infections
  • cytomegalovirus, herpes simplex virus, varicella-zoster virus) in Sande MA and Volberding PA
  • (eds): The Medical Management of AIDS. W.B. Saunders Company, Philadelphia, 1990, pp. 316-
  • 338.
  • 18. Drew WL.: Viral Infections (sec 6.4.2. - 6.4.8). In: Cohen PT et al (eds): The AIDS
  • Knowledge Base. A Textbook on HIV Disease, from the University of California, San Francisco,
  • and the San Francisco General Hospital. The Medical Publishing Group, Waltham, Massachusetts,
  • 1990.
  • 19. Drew WL. Laboratory Methods in Basic Virology, In Baron EJ and Feingold M
  • eds): Diagnostic Microbiology. Baily and Scott, St. Louis, pp. 641 - 680, 1990.
  • 20. Drew WL, Buhles W, and Ehrlich KS: Management of virus infections (cytomegalovirus,
  • herpes simplex virus, varicella-zoster virus) in Sande MA and Volberding PA (eds): The Medical
  • Management of AIDS. (third and fourth editions) W.B. Saunders Company, Philadelphia, 1992:
  • 1995.
  • 21. Drew WL. Diagnosis and treatment of cytomegalovirus (CMV) infections, in Mills and
  • Corey (eds): Antiviral Chemotherapy. New Directions for Clinical Application and Research.
  • (second edition) Elsevier, New York, 1992.
  • 30
  • 22. Drew WL. Cytomegalovirus (CMV) infection and therapy in immunocompromised
  • patients, in Sande MA and Root R (eds): Contemporary Issues in Infectious Diseases. Churchill
  • Livingstone Inc., New York, 1992.
  • 23. Drew WL. Cytomegalovirus as a Sexually Transmitted Disease, in Becker Y, Darai G, and
  • Huang E-S (eds): Molecular Aspects of Human Cytomegalovirus Disease. Springer-Verlag, Berlin,
  • pp. 92 - 100, 1993.
  • 24. Drew WL, et al. The safety, pharmacokinetics, and anti-CMV activity of weekly HPMPC
  • in HIV positive patients excreting CMV, in Michelson and Plotkin (eds): Multidisciplinary
  • Approach to Understanding Cytomegalovirus Disease. Elsevier Science Publishers, Amsterdam,
  • pp. 287-292, 1993.
  • 25. Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJM, Drew WL: A preclinical overview of the
  • nucleotide-based antiviral agent cidofovir (HPMPC) in Corey L and Mills J (eds): New Directions
  • in Antiviral Chemotherapy. Plenum Inc., New York, 1995.
  • 26. Drew WL. Cytomegalovirus, in Kelley (ed): Textbook of Internal Medicine. Third
  • Edition, J.B. Lippincott Co., Philadelphia, 1997.
  • 27. Drew WL. Cytomegalovirus, in Holmes, Sparling, Mardh, et al (eds): Sexually
  • Transmitted Diseases, Third Edition, The McGraw-Hill Companies, New York, 313-320, 1999.
  • 28. Drew WL and Buhles WC. Nucleosides and foscarnet -- Clinical aspects, in Richman DD,
  • (ed): Antiviral Drug Resistance, John Wiley and Sons, Chichester, pp 153-165,1996.
  • 29. Biron KK, Baldanti F, Drew WL. Human cytomegalovirus -- Antiviral agents:
  • Mechanisms of action and drug resistance, in Jager H (ed): Cytomegalie und AIDS, Thieme-
  • Verlag, Stuttgart, New York, pp. 25-41, 1998.
  • 30. Drew WL and Lalezari J. Cytomegalovirus disease syndromes and treatment, in Current
  • Clinical Topics in Infectious Disease, pp. 16-29, 1999.
  • 31. Drew WL. Human cytomegalovirus and HIV, in Lalezari and Moyle (eds): Viral Coinfections
  • in HIV: Impact and Management. Remedica Publishing, London, pp. 5-33, 2001.
  • 32. Drew WL. Cytomegalovirus, in Goldman and Ausiello (eds): Cecil Medicine, Saunders
  • Elsevier, Philadelphia, pp. 2505-7, 2008.
  • 33. Drew WL and Erlich KS. Management of herpesvirus infections (cytomegalovirus, herpes
  • simplex virus, and varicella-zoster virus), in Volberding PA et al, (eds): Global HIV/AIDS
  • Medicine, Saunders Elsevier, Philadelphia, pp. 437-61, 2008.
  • 34. Drew WL. Human cytomegalovirus and HIV, in Lalezari and Moyle (eds): Viral Coinfections
  • in HIV: Impact and Management. Second Edition, Remedica Publishing, London,
  • 2008.
  • 31
  • 35. Boivin G and Drew WL. Herpesvirus resistance, in Antimicrobial Drug Resistance,
  • Humana Press, 2009.
  • 36. Drew WL. Cytomegalovirus, in Goldman and Schafer (eds): Goldman’s Cecil Medicine,
  • Elsevier Saunders, Philadelphia, pp. 2131-33, 2011.

Military service

  • GOVERNMENT SERVICE:
  • 1. NIH Workshop on AIDS epidemiology - 1982
  • 2. NIH Workshop - Etiology of AIDS - February 1982
  • 3. NIH - AIDS Workshops, Etiology, April 1983
  • 4. NIH - Ad Hoc committee meeting to review cooperative agreement applications "Studies
  • of Acquired Immunodeficiency Syndrome" -December 1985
  • 5. AIDS Advisory Committee, San Francisco Dept. of Public Health, 1986-1988
  • 6. NIAID Workshop - Pathogenesis of AIDS, Possible Cofactors. Interactions of CMV and
  • HTLV-III. - April 1986
  • 8. NIH Workshop - Antiviral Resistance, October 1990
  • 9. NIH Review Committee – 1990
  • 10. Member, National Respiratory and Enteric Virus Surveillance System (NREVSS) 1990-
  • Present
  • 11. Program and organizing committee XVI International Herpesvirus Workshop, Asilomar,
  • CA, July 1991.
  • 12. External reviewer for the National Health Research and Development Program (NHRDP),
  • Health Programs and Services Branch, Canada, 2000
  • 13. NIH Consultant - Prevention of Opportunistic Infections, Atlanta, GA, September 1994 to
  • present.
  • 14. Israel Science Foundation, Research Proposal Review Committee, 2001
  • 15. National Respiratory and Enteric Virus Surveillance System, 1995 – present
  • 16. California Influenza Surveillance Project, 2000 - present
  • 17. Testified before the California Senate Select Committee on West Nile Virus, May 2005

Listed in the Following States

WILLIAM LAWRENCE DREW, M.D., Ph.D. is listed with ExpertPages in the following jurisdictions: All US Regions and States, Canada (all Provinces).